Safety and activity of ibrutinib plus rituximab for patien lymphocytic leukaemia: a single-arm, phase 2 study

Lancet Oncology, The

15, 1090-1099

DOI: 10.1016/s1470-2045(14)70335-3

Citation Report

#	Article	IF	Citations
1	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
2	Ibrutinib: a paradigm shift in management of CLL. Expert Review of Hematology, 2014, 7, 705-717.	1.0	17
3	Recent Advances in the Pathogenesis and Treatment of Chronic Lymphocytic Leukemia. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2014, 35, 105-120.	0.2	2
4	New Strategies in Chronic Lymphocytic Leukemia: Shifting Treatment Paradigms. Clinical Cancer Research, 2014, 20, 5869-5874.	3.2	45
5	Transplantation in Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America, 2014, 28, 1055-1071.	0.9	2
6	Ibrutinib: better combined with other drugs?. Lancet Oncology, The, 2014, 15, 1043-1044.	5.1	4
7	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. Blood, 2014, 124, 3841-3849.	0.6	185
8	Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood, 2014, 124, 3829-3830.	0.6	313
9	Prognostic markers and standard management of chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 2015, 2015, 368-377.	0.9	29
10	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood, 2015, 125, 2062-2067.	0.6	303
11	Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood, 2015, 126, 842-850.	0.6	125
12	Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib. Blood, 2015, 125, 1673-1673.	0.6	17
13	Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood, 2015, 126, 471-477.	0.6	112
14	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood, 2015, 126, 1921-1924.	0.6	197
15	Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies. Oncology Letters, 2015, 10, 3339-3344.	0.8	10
16	Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinibâ€based regimens. Cancer, 2015, 121, 3612-3621.	2.0	220
17	The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica, 2015, 100, 1495-1507.	1.7	81
18	Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies. Current Opinion in Oncology, 2015, 27, 365-370.	1.1	3

#	Article	IF	Citations
19	Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomarker Insights, 2015, 10s3, BMI.S22430.	1.0	29
20	First case of mesh infection due to Coccidioides spp. and literature review of fungal mesh infections after hernia repair. Mycoses, 2015, 58, 582-587.	1.8	3
21	Ofatumumab retreatment and maintenance in fludarabineâ€refractory chronic lymphocytic leukaemia patients. British Journal of Haematology, 2015, 170, 40-49.	1.2	14
22	Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia. Biologics: Targets and Therapy, 2015, 9, 75.	3.0	2
23	Targetting BTK/PI-3KÎ´ in CLL. Hematologie, 2015, 21, 117-126.	0.0	0
24	A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Therapeutics and Clinical Risk Management, 2015, 11, 979.	0.9	24
25	Management of Chronic Lymphocytic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 164-175.	1.8	24
26	New Insights in Prognosis and Therapy of Chronic Lymphocytic Leukaemia. , 0, , .		0
27	Rethinking Clinical Response and Outcome Assessment in a Biologic Age. Current Oncology Reports, 2015, 17, 27.	1.8	3
28	Integrating Oncogeriatric Tools into the Management of Chronic Lymphocytic Leukemia: Current State of the Art and Challenges for the Future. Current Oncology Reports, 2015, 17, 31.	1.8	3
29	Targeting neoplastic B cells and harnessing microenvironment: the â€œdouble faceâ€•of ibrutinib and idelalisib. Journal of Hematology and Oncology, 2015, 8, 60.	6.9	49
30	How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/orTP53mutation?. Leukemia and Lymphoma, 2015, 56, 587-593.	0.6	18
31	Novel therapeutic options for relapsed hairy cell leukemia. Leukemia and Lymphoma, 2015, 56, 2264-2272.	0.6	13
32	Ibrutinib in chronic lymphocytic leukemia. International Journal of Hematologic Oncology, 2015, 4, 143-150.	0.7	0
33	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncology, The, 2015, 16, 169-176.	5.1	344
34	Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia, 2015, 29, 1602-1604.	3.3	214
35	Targeted Therapy for Chronic Lymphocytic Leukemia: Current Status and Future Directions. Drugs, 2015, 75, 143-155.	4.9	4
36	New oral small molecules in the treatment of chronic lymphocytic leukemia. Cancer, 2015, 121, 1917-1926.	2.0	2

#	Article	IF	Citations
37	Ibrutinib for the treatment of WaldenstrÃ¶m macroglobulinemia. Expert Review of Hematology, 2015, 8, 569-579.	1.0	14
38	The preclinical discovery of rituximab for the treatment of non-Hodgkinâ€™s lymphoma. Expert Opinion on Drug Discovery, 2015, 10, 791-808.	2.5	7
39	Ibrutinib in B lymphoid malignancies. Expert Opinion on Pharmacotherapy, 2015, 16, 1879-1887.	0.9	28
40	Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs, 2015, 20, 423-447.	1.0	9
41	B-cell receptor signaling in the pathogenesis of lymphoid malignancies. Blood Cells, Molecules, and Diseases, 2015, 55, 255-265.	0.6	22
42	Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and nonâ€Hodgkin lymphoma. British Journal of Haematology, 2015, 170, 445-456.	1.2	76
43	Where Does Allogeneic Stem Cell Transplantation Fit in the Treatment of Chronic Lymphocytic Leukemia?. Current Hematologic Malignancy Reports, 2015, 10, 59-64.	1.2	13
44	Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. American Journal of Hematology, 2015, 90, 446-460.	2.0	212
45	Targeting Bruton's tyrosine kinase with ibrutinib in Bâ€cell malignancies. Clinical Pharmacology and Therapeutics, 2015, 97, 455-468.	2.3	49
46	Ibrutinib: A Review of Its Use in Patients with Mantle Cell Lymphoma or Chronic Lymphocytic Leukaemia. Drugs, 2015, 75, 769-776.	4.9	35
47	Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2015, 21, 3705-3715.	3.2	183
48	The biology behind PI3K inhibition in chronic lymphocytic leukaemia. Therapeutic Advances in Hematology, 2015, 6, 25-36.	1.1	13
49	Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. Haematologica, 2015, 100, e140-e142.	1.7	61
50	Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide. Expert Review of Hematology, 2015, 8, 765-783.	1.0	3
51	Predictive biomarkers in precision medicine and drug development against lung cancer. Chinese Journal of Cancer, 2015, 34, 295-309.	4.9	34
52	Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution. Bioanalysis, 2015, 7, 2713-2724.	0.6	32
53	What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?. Expert Review of Hematology, 2015, 8, 733-742.	1.0	9
54	Treatment with Ibrutinib Inhibits BTK- and VLA-4â€“Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo. Clinical Cancer Research, 2015, 21, 4642-4651.	3.2	97

#	Article	IF	Citations
55	PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). Current Topics in Microbiology and Immunology, 2015, 393, 123-142.	0.7	46
56	The clinical safety of ibrutinib in chronic lymphocytic leukemia. Expert Opinion on Drug Safety, 2015, 14, 1621-1629.	1.0	6
57	Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?. Expert Review of Hematology, 2015, 8, 743-764.	1.0	0
58	Achieving incompatible transplantation through desensitization: current perspectives and future directions. Immunotherapy, 2015, 7, 377-398.	1.0	22
59	How I treat chronic lymphocytic leukemia in older patients. Journal of Geriatric Oncology, 2015, 6, 333-340.	0.5	6
60	Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial. Expert Review of Anticancer Therapy, 2015, 15, 9-15.	1.1	5
61	11. Chronic lymphocytic leukemia. , 2016, , 205-228.		0
62	BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016011.	0.5	17
63	Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget, 2016, 7, 65968-65981.	0.8	84
64	Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e387-e398.	1.8	22
66	Retour de congrÃ¨s Atelier international sur la leucÃ©mie lymphoÃ¯de chronique (IWCLL) 2015, Sydney. Hematologie, 2016, 22, 210-217.	0.0	0
67	Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer Journal (Sudbury, Mass), 2016, 22, 34-39.	1.0	25
68	Stable isotopeâ€labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults. British Journal of Clinical Pharmacology, 2016, 81, 235-245.	1.1	56
69	Recent advances in therapy of chronic lymphocytic leukaemia. British Journal of Haematology, 2016, 174, 351-367.	1.2	18
70	Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica, 2016, 101, e254-e258.	1.7	40
71	Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood, 2016, 128, 2899-2908.	0.6	70
72	Advances in the treatment of chronic lymphocytic leukaemia. Medicina ClÃ¡nica (English Edition), 2016, 147, 447-454.	0.1	0
73	Sequencing of chronic lymphocytic leukemia therapies. Hematology American Society of Hematology Education Program, 2016, 2016, 128-136.	0.9	14

#	Article	IF	Citations
74	Prognostication of chronic lymphocytic leukemia in the era of new agents. Hematology American Society of Hematology Education Program, 2016, 2016, 149-155.	0.9	30
75	Novel agents in chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 2016, 2016, 137-145.	0.9	14
76	Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade. Seminars in Oncology, 2016, 43, 222-232.	0.8	23
77	Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma. Leukemia and Lymphoma, 2016, 57, 2914-2916.	0.6	24
78	Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises. Immunotherapy, 2016, 8, 569-581.	1.0	14
79	Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica, 2016, 101, 531-540.	1.7	75
80	Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies. Current Hematologic Malignancy Reports, 2016, 11, 318-325.	1.2	2
81	Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014). Journal of Clinical Oncology, 2016, 34, 1928-1934.	0.8	47
82	Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood, 2016, 127, 208-215.	0.6	571
83	Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood, 2016, 127, 279-286.	0.6	105
85	B cell receptor inhibition as a target for CLL therapy. Best Practice and Research in Clinical Haematology, 2016, 29, 2-14.	0.7	9
86	Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1381-1392.	1.5	30
87	Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. Best Practice and Research in Clinical Haematology, 2016, 29, 54-66.	0.7	7
88	Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood, 2016, 128, 1609-1613.	0.6	85
89	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 2117-2125.	2.0	87
90	Current strategies to create tailored and risk-adapted therapies for CLL patients. Best Practice and Research in Clinical Haematology, 2016, 29, 111-121.	0.7	3
92	Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. Journal of Immunology, 2016, 197, 2522-2531.	0.4	31
93	Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S74-S81.	0.2	18

#	Article	IF	Citations
94	TP53 dysfunction in CLL: Implications for prognosis and treatment. Best Practice and Research in Clinical Haematology, 2016, 29, 90-99.	0.7	14
95	The safety profile of monoclonal antibodies for chronic lymphocytic leukemia. Expert Opinion on Drug Safety, 2017, 16, 1-17.	1.0	3
96	Hematopoietic Cell Transplantation for Richter Syndrome. Biology of Blood and Marrow Transplantation, 2016, 22, 1938-1944.	2.0	11
97	Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 346-357.	0.7	24
98	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nature Communications, 2016, 7, 11589.	5.8	285
99	New emerging therapies in the management of chronic lymphocytic leukemia. Oncology Letters, 2016, 12, 3051-3054.	0.8	2
100	The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia. Expert Review of Hematology, 2016, 9, 1177-1187.	1.0	2
101	Bruton's tyrosine kinase inhibitor restrains Wnt signaling in chronic lymphocytic leukemia. Molecular Medicine Reports, 2016, 13, 4934-4938.	1.1	12
102	Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis. Annals of Hematology, 2016, 95, 1473-1482.	0.8	9
103	Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?. Expert Review of Hematology, 2016, 9, 679-693.	1.0	2
104	Integration of Chinese Herbal Medicine Therapy Improves Survival of Patients With Chronic Lymphocytic Leukemia. Medicine (United States), 2016, 95, e3788.	0.4	16
105	The relation of illness perceptions to stress, depression, and fatigue in patients with chronic lymphocytic leukaemia. Psychology and Health, 2016, 31, 891-902.	1.2	19
106	Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.0	4
107	Targeted therapies for CLL: Practical issues with the changing treatment paradigm. Blood Reviews, 2016, 30, 233-244.	2.8	63
108	Ibrutinib in chronic lymphocytic leukaemia: alone or in combination?. Lancet Oncology, The, 2016, 17, 129-131.	5.1	10
109	Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 63-69.	0.2	7
110	Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcî³ Receptor (Fcî³R) Function. Journal of Biological Chemistry, 2016, 291, 3043-3052.	1.6	61
111	Ibrutinib for treatment of chronic lymphocytic leukemia. American Journal of Health-System Pharmacy, 2016, 73, 367-375.	0.5	12

#	Article	IF	Citations
112	Chronic lymphocytic leukemia therapy: new targeted therapies on the way. Expert Opinion on Pharmacotherapy, 2016, 17, 1077-1089.	0.9	13
113	Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study. Leukemia and Lymphoma, 2016, 57, 1585-1591.	0.6	11
114	<scp>C</scp>hronic lymphocytic leukemia (CLL)â€"<scp>T</scp>hen and now. American Journal of Hematology, 2016, 91, 330-340.	2.0	116
115	Advances in firstâ€line treatment of chronic lymphocytic leukemia: current recommendations on management and firstâ€line treatment by the German <scp>CLL</scp> Study Group (<scp>GCLLSG</scp>). European Journal of Haematology, 2016, 96, 9-18.	1.1	28
116	Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia. Seminars in Oncology, 2016, 43, 251-259.	0.8	31
117	Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia. Seminars in Oncology, 2016, 43, 280-290.	0.8	25
119	Initial therapy of chronic lymphocytic leukemia. Seminars in Oncology, 2016, 43, 241-250.	0.8	11
120	B Cell Receptor Signaling. Current Topics in Microbiology and Immunology, 2016, , .	0.7	1
121	mTOR Inhibition for Cancer Therapy: Past, Present and Future. , 2016, , .		3
122	Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 48-56.	5.1	189
123	Ibrutinib-A double-edge sword in cancer and autoimmune disorders. Journal of Drug Targeting, 2016, 24, 373-385.	2.1	21
124	CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. Leukemia and Lymphoma, 2016, 57, 563-571.	0.6	34
125	Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. Clinical Cancer Research, 2016, 22, 86-95.	3.2	75
126	Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 401-413.	1.9	175
127	Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia. Journal of Oncology Pharmacy Practice, 2017, 23, 502-517.	0.5	4
128	Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 4527-4533.	3.2	56
129	Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. Journal of Immunology, 2017, 198, 1740-1747.	0.4	92
130	Human NACHT, LRR, and PYD domainâ€"containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. Journal of Allergy and Clinical Immunology, 2017, 140, 1054-1067.e10.	1.5	105

#	Article	IF	Citations
131	Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A realâ€world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group. American Journal of Hematology, 2017, 92, E105-E107.	2.0	12
132	Management of atrial fibrillation in patients taking targeted cancer therapies. Cardio-Oncology, 2017, 3, 2.	0.8	19
133	Longâ€term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer, 2017, 123, 2268-2273.	2.0	103
134	Targeted Therapy in Chronic Lymphocytic Leukemia (CLL). Current Hematologic Malignancy Reports, 2017, 12, 20-28.	1.2	6
135	Magic pills: new oral drugs to treat chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy, 2017, 18, 411-425.	0.9	9
136	Current Treatment of Chronic Lymphocytic Leukemia. Current Treatment Options in Oncology, 2017, 18, 5.	1.3	17
137	Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era. Blood Reviews, 2017, 31, 318-327.	2.8	15
138	Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma. Current Hematologic Malignancy Reports, 2017, 12, 207-216.	1.2	10
139	Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy, 2017, 18, 857-873.	0.9	2
140	Current Status of Brutonâ€™s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. Drugs and Aging, 2017, 34, 509-527.	1.3	34
141	Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 15746.	5.8	93
142	Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future. Expert Review of Hematology, 2017, 10, 425-432.	1.0	5
143	Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. Annals of Hematology, 2017, 96, 1175-1184.	0.8	55
144	Targeting of Bâ€cell receptor signalling in Bâ€cell malignancies. Journal of Internal Medicine, 2017, 282, 415-428.	2.7	37
145	Ublituximab (<scp>TG</scp>â€1101), a novel glycoengineered antiâ€<scp>CD</scp>20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. British Journal of Haematology, 2017, 176, 412-420.	1.2	58
146	Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs, 2017, 26, 1249-1265.	1.9	31
147	Combination therapy with the type II anti-CD20 antibody obinutuzumab. Expert Opinion on Investigational Drugs, 2017, 26, 1145-1162.	1.9	6
148	Will combination therapy with targeted drugs be better for achieving remission in chronic lymphocytic leukemia?. Expert Opinion on Pharmacotherapy, 2017, 18, 1675-1678.	0.9	1

#	Article	IF	Citations
149	Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. Current Oncology Reports, 2017, 19, 61.	1.8	14
150	Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. American Journal of Hematology, 2017, 92, 946-965.	2.0	229
151	Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica, 2017, 102, 1629-1639.	1.7	111
152	Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia. Leukemia, 2017, 31, 837-845.	3.3	49
153	Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leukemia and Lymphoma, 2017, 58, 1376-1383.	0.6	33
154	Increased Fcî³RIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients. Oncogene, 2017, 36, 2366-2376.	2.6	10
155	Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia. Leukemia and Lymphoma, 2017, 58, 1548-1560.	0.6	23
156	Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 2154-2158.	3.2	47
157	Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 1049-1059.	3.2	36
158	Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 31-37.e13.	0.2	77
159	The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nature Communications, 2017, 8, 2185.	5.8	148
160	Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant. Case Reports in Oncology, 2017, 10, 534-541.	0.3	11
161	Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Advances, 2017, 1, 715-727.	2.5	105
162	Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Advances, 2017, 1, 772-778.	2.5	82
163	Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. Drug Design, Development and Therapy, 2017, Volume11, 295-304.	2.0	15
164	Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?. Frontiers in Immunology, 2017, 8, 1245.	2.2	124
165	Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017. BMC Medicine, 2017, 15, 156.	2.3	3
166	Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia. OncoTargets and Therapy, 2017, Volume 10, 1909-1914.	1.0	6

#	Article	IF	Citations
167	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Advances, 2017, 1, 1739-1748.	2.5	123
168	Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia. Journal of Oncology Practice, 2017, 13, 371-377.	2.5	16
169	Chronic lymphocytic leukaemia. Lancet, The, 2018, 391, 1524-1537.	6.3	233
170	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. Hematological Oncology, 2018, 36, 624-632.	0.8	55
171	Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. Clinical Infectious Diseases, 2018, 67, 687-692.	2.9	210
172	Ublituximab for the treatment of CD20 positive B-cell malignancies. Expert Opinion on Investigational Drugs, 2018, 27, 407-412.	1.9	38
173	Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica, 2018, 103, 698-706.	1.7	63
175	Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. European Journal of Haematology, 2018, 100, 325-334.	1.1	107
176	Ibrutinib and its use in the treatment of chronic lymphocytic leukemia. Future Oncology, 2018, 14, 681-697.	1.1	0
177	Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia. Therapeutic Advances in Hematology, 2018, 9, 3-19.	1.1	19
178	Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study. Leukemia and Lymphoma, 2018, 59, 2075-2084.	0.6	13
179	Critical molecular pathways in CLL therapy. Molecular Medicine, 2018, 24, 9.	1.9	33
180	Role of Brutonâ€™s tyrosine kinase in B cells and malignancies. Molecular Cancer, 2018, 17, 57.	7.9	435
181	Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies. Blood Reviews, 2018, 32, 499-507.	2.8	57
182	Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab. Internal Medicine, 2018, 57, 2395-2398.	0.3	14
183	Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments. Leukemia, 2018, 32, 1307-1316.	3.3	19
184	Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. Blood Reviews, 2018, 32, 387-399.	2.8	54
185	Venetoclaxâ€“Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2018, 378, 1107-1120.	13.9	684

#	Article	IF	Citations
186	CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncology, 2018, 14, 499-513.	1.1	27
187	Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management. Leukemia and Lymphoma, 2018, 59, 311-320.	0.6	33
188	Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2018, 59, 300-310.	0.6	7
189	Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies. Hematology/ Oncology and Stem Cell Therapy, 2018, 11, 1-12.	0.6	7
190	Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e35-e39.	0.2	18
191	Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG) Tj ETQq1 1 0.784314 rgBT /Ov abbreviated frontline therapy with FCR in non-del(17p) CLL. Leukemia and Lymphoma, 2018, 59, 1338-1347.	0.6	7
192	Chronic lymphocytic leukemia is becoming more complex: how to define complex karyotype?. Leukemia and Lymphoma, 2018, 59, 521-522.	0.6	3
193	Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leukemia and Lymphoma, 2018, 59, 1554-1564.	0.6	43
194	The mTOR kinase inhibitor everolimus synergistically enhances the antiâ€tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLSâ€123 on Mantle cell lymphoma. International Journal of Cancer, 2018, 142, 202-213.	2.3	21
195	Management of hypogammaglobulinemia and recurrent infections in a chronic lymphocytic leukemia patient receiving ibrutinib. Annals of Allergy, Asthma and Immunology, 2018, 120, 324-325.	0.5	4
196	Advances in chronic lymphocytic leukemia pharmacotherapy. Biomedicine and Pharmacotherapy, 2018, 97, 349-358.	2.5	9
197	Brutonâ€™s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opinion on Investigational Drugs, 2018, 27, 31-42.	1.9	57
198	Toward the potential cure of leukemias in the next decade. Cancer, 2018, 124, 4301-4313.	2.0	36
199	Next-Generation in vivo Modeling of Human Cancers. Frontiers in Oncology, 2018, 8, 429.	1.3	33
200	Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation. Annals of Hematology, 2018, 97, 2269-2278.	0.8	32
201	The Genomic Landscape of Chronic Lymphocytic Leukaemia: Clinical Implications. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S112-S115.	0.2	1
202	Ibrutinib-Associated Atrial Fibrillation. JACC: Clinical Electrophysiology, 2018, 4, 1491-1500.	1.3	134
203	Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia. Leukemia and Lymphoma, 2018, 59, 2792-2800.	0.6	28

#	Article	IF	Citations
204	Evolution of CLL treatment â€" from chemoimmunotherapy to targeted and individualized therapy. Nature Reviews Clinical Oncology, 2018, 15, 510-527.	12.5	114
205	The future of chronic lymphocytic leukemia: potential directions from ASH 2017. Expert Review of Hematology, 2018, 11, 481-486.	1.0	0
206	An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 508-518.e14.	0.2	11
207	Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma. Molecular Cancer Therapeutics, 2018, 17, 2156-2163.	1.9	38
208	Small Molecules in Hematology. Recent Results in Cancer Research, 2018, , .	1.8	6
209	Ibrutinib. Recent Results in Cancer Research, 2018, 212, 133-168.	1.8	31
210	Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood, 2018, 132, 1039-1049.	0.6	51
211	The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opinion on Biological Therapy, 2018, 18, 973-982.	1.4	7
212	Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies. Cancer Immunology Research, 2018, 6, 1150-1160.	1.6	57
213	Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 803-813.e7.	0.2	32
214	Cytopenias: Reactive and Neoplastic. , 2018, , 17-79.		1
215	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticÂleukaemia treated with ibrutinib from 3 clinical trials. British Journal of Haematology, 2018, 182, 504-512.	1.2	37
216	Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials. Leukemia and Lymphoma, 2018, 59, 2769-2781.	0.6	14
217	Advances in drugâ€based therapies in chronic lymphocytic leukemia and future prospects. Advances in Cell and Gene Therapy, 2019, 2, e51.	0.6	0
218	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. , 2019, , 185-190.		1
219	Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. American Journal of Hematology, 2019, 94, 1266-1287.	2.0	352
220	Ibrutinibâ€related atrial fibrillation: A single center Australian experience. Asia-Pacific Journal of Clinical Oncology, 2019, 15, e187-e190.	0.7	6
221	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biology of Blood and Marrow Transplantation, 2019, 25, 2002-2007.	2.0	64

#	Article	IF	Citations
223	Putative link between Polo-like kinases (PLKs) and Toll-like receptor (TLR) signaling in transformed and primary human immune cells. Scientific Reports, 2019, 9, 13168.	1.6	3
224	Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. Frontiers in Oncology, 2019, 9, 443.	1.3	25
225	Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2019, 68, 1839-1853.	2.0	34
226	Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. Leukemia Research, 2019, 81, 88-94.	0.4	11
228	Ibrutinib for the treatment of chronic lymphocytic leukemia. Expert Review of Hematology, 2019, 12, 273-284.	1.0	3
229	Inhibiting Brutonâ€™s Tyrosine Kinase in CLL and Other B-Cell Malignancies. Targeted Oncology, 2019, 14, 125-138.	1.7	33
230	Management of adverse effects/toxicity of ibrutinib. Critical Reviews in Oncology/Hematology, 2019, 136, 56-63.	2.0	95
231	New Protein Markers of Chronic Lymphocytic and Acute Lymphocytic Leukemia. , 0, , .		0
232	Antiâ€“BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Advances, 2019, 3, 447-460.	2.5	42
233	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood Advances, 2019, 3, 1568-1573.	2.5	26
234	Crossâ€talk between Myc and p53 in Bâ€cell lymphomas. Chronic Diseases and Translational Medicine, 2019, 5, 139-154.	0.9	16
235	From Biology to Therapy: The CLL Success Story. HemaSphere, 2019, 3, e175.	1.2	55
236	PI3KÎ´ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. Leukemia, 2019, 33, 1427-1438.	3.3	51
237	The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. Leukemia, 2019, 33, 287-298.	3.3	39
238	CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia, 2019, 33, 1161-1172.	3.3	38
239	Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?. Blood, 2019, 133, 121-129.	0.6	18
240	Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Lancet Haematology,the, 2019, 6, e67-e78.	2.2	146
241	Ibrutinib significantly inhibited Brutonâ€™s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. OncoImmunology, 2019, 8, e1512455.	2.1	17

#	Article	IF	Citations
242	Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood, 2019, 133, 1011-1019.	0.6	168
243	Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leukemia and Lymphoma, 2019, 60, 1000-1005.	0.6	17
244	Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia. Molecular Immunology, 2019, 110, 77-87.	1.0	24
245	Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia. Expert Review of Hematology, 2020, 13, 39-53.	1.0	6
246	Ibrutinib in B-cell lymphoma: single fighter might be enough?. Cancer Cell International, 2020, 20, 467.	1.8	16
247	IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. Blood Advances, 2020, 4, 5093-5106.	2.5	4
248	Potential strategies against resistance to CAR T-cell therapy in haematological malignancies. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096296.	1.4	7
249	An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia. Expert Opinion on Pharmacotherapy, 2020, 21, 1555-1564.	0.9	2
250	Synergistic effect of ibrutinib and CD19 CARâ€T cells on Raji cells in vivo and in vitro. Cancer Science, 2020, 111, 4051-4060.	1.7	19
251	LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. Annals of Hematology, 2020, 99, 2343-2349.	0.8	3
252	Relevant Cytokines in the B Cell Lymphoma Micro-Environment. Cancers, 2020, 12, 2525.	1.7	6
253	Management of Ibrutinib Toxicities: a Practical Guide. Current Hematologic Malignancy Reports, 2020, 15, 177-186.	1.2	24
254	The regulation and function of CD20: an â€œenigmaâ€•of B-cell biology and targeted therapy. Haematologica, 2020, 105, 1494-1506.	1.7	186
255	Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies. Leukemia, 2020, 34, 2934-2950.	3.3	16
256	Ibrutinib in primary central nervous systemÂdiffuse large B-cell lymphoma. CNS Oncology, 2020, 9, CNS51.	1.2	9
257	Dermatological Toxicities of Brutonâ€™s Tyrosine Kinase Inhibitors. American Journal of Clinical Dermatology, 2020, 21, 799-812.	3.3	50
258	Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL. Nature Communications, 2020, 11, 577.	5.8	69
259	A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. Future Oncology, 2021, 17, 255-262.	1.1	13

#	Article	IF	Citations
260	Effects of CD20 antibodies and kinase inhibitors on Bâ€cell receptor signalling and survival of chronic lymphocytic leukaemia cells. British Journal of Haematology, 2021, 192, 333-342.	1.2	5
261	Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies. Leukemia and Lymphoma, 2021, 62, 984-987.	0.6	2
262	Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study. British Journal of Haematology, 2021, 193, 316-324.	1.2	12
263	Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. Critical Reviews in Oncology/Hematology, 2021, 158, 103203.	2.0	4
264	Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2021, 62, 1786-1789.	0.6	2
265	Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 159, 103238.	2.0	14
266	Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer Journal, 2021, 11, 79.	2.8	36
267	Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma. Cancer Cell International, 2021, 21, 195.	1.8	6
268	The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment. Diagnostics, 2021, 11, 853.	1.3	15
269	Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management. Toxicology Research, 2021, 10, 476-486.	0.9	16
270	Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. Molecular Therapy - Oncolytics, 2021, 21, 158-170.	2.0	22
271	Targeting Brutonâ€™s Tyrosine Kinase in CLL. Frontiers in Immunology, 2021, 12, 687458.	2.2	40
272	The future of antibody therapy in chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs, 2021, 26, 323-336.	1.0	2
273	Progress in the development of small molecular inhibitors of the Brutonâ€™s tyrosine kinase (BTK) as a promising cancer therapy. Bioorganic and Medicinal Chemistry, 2021, 47, 116358.	1.4	22
275	Recent therapeutic advances in chronic lymphocytic leukemia. F1000Research, 2017, 6, 1924.	0.8	13
276	Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review. Journal of Hematology (Brossard, Quebec), 2019, 8, 1-10.	0.4	5
277	Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma. Oncotarget, 2015, 6, 42232-42242.	0.8	31
278	Promises and pitfalls of targeted agents in chronic lymphocytic leukemia. , 2020, 3, 415-444.		5

#	Article	IF	Citations
280	Chronic lymphocytic leukemia: a clinical review including Korean cohorts. Korean Journal of Internal Medicine, 2016, 31, 433-443.	0.7	11
281	Efficacy and safety of ibrutinib in indian patients with relapsed or refractory chronic lymphocytic leukemia and mantle cell lymphoma: Cases from a named patient program. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 508.	0.1	7
282	Burton's Tyrosine Kinase Inhibition by Ibrutinib: Current Status. Journal of Leukemia (Los Angeles,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.1	1
283	Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. American Journal of Hematology, 2021, 96, 1679-1705.	2.0	150
284	Targeted Therapy in Lymphoproliferative Disorders (Excluding CAR T Cells). , 2015, 12, .		0
285	A New Challenger for FCR in CLL: Ibrutinib + Rituximab. , 2015, 12, .		0
286	Current Status in Management of Patients with Chronic Lymphocytic Leukemia (CLL) in Republic of Macedonia. Makedonski Medicinski Pregled Revue Medicale Macedonienne, 2016, 70, 30-34.	0.0	0
287	The Role of PI3K/AKT/mTOR Inhibitors in the Treatment of Hematological Malignancies. , 2016, , 139-160.		0
289	Ibrutinib in hematoonkology. Klinicka Farmakologie A Farmacie, 2016, 30, 8-14.	0.1	1
290	B-Cell Receptors. Molecular and Translational Medicine, 2018, , 61-89.	0.4	0
291	Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2018, 11, 42-49.	0.1	2
292	Resistance to Brutonâ€™s Tyrosine Kinase Signaling Pathway Targeted Therapies. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 111-153.	0.1	1
293	Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia. Hematologic Malignancies, 2019, , 107-119.	0.2	1
294	CLL with Del (17p)/TP53 Mutation. Hematologic Malignancies, 2019, , 97-106.	0.2	0
295	Maintenance therapy for chronic lymphocytic leukaemia. The Cochrane Library, 0, , .	1.5	1
296	Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia. , 2020, 3, 532-549.		0
297	Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management. Hematological Oncology, 2022, 40, 129-159.	0.8	4
298	Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab. Haematologica, 2021, 106, 1500-1503.	1.7	7

#	Article	IF	Citations
301	The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact. Haematologica, 2022, 107, 1460-1465.	1.7	2
302	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. Cancers, 2022, 14, 207.	1.7	3
305	Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance. Blood and Lymphatic Cancer: Targets and Therapy, 0, Volume 12, 81-98.	1.2	3
306	A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma. Leukemia and Lymphoma, 0, , 1-4.	0.6	0
307	Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition). Frontiers of Medicine, 2022, 16, 815-826.	1.5	1
308	Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nature Genetics, 2022, 54, 1664-1674.	9.4	52
309	Hide and Seek: The Game Between Chronic Lymphocytic Leukaemia Cells and B Cell Receptor Signalling Inhibitors. European Medical Journal (Chelmsford, England), 0, , 24-30.	3.0	1
310	A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia, 0, , .	3.3	1